Merck’s Tulisokibart Meets Phase 2b Primary Endpoint In Hidradenitis Suppurativa, Achieves HiSCR50 of 72% And 64% Vs 35% for Placebo At Week 16
Results mark the first positive Phase 2 data for an anti-TL1A monoclonal antibody in dermatologyTulisokibart was designed to help address immuno-fibrosis, a key driver of disease progression in HSMerck (NYSE:MRK), known
Merck's new skin medicine worked better than a fake pill in testing. This is good progress and shows the drug might help people with a painful skin condition.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.